SAFETY HARBOR, Fla., Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strategic and valuable Management Services Organization ("MSO") agreement with FDA licensed manufacturer of pharmaceutical products. This agreement enables MedWell USA to act as a Procurement Agent for Semaglutide, a leading pharmaceutical product in the weight management sector. MedWell USA will leverage various mar ...

Terns has a modest market cap of less than $800 million, and its possible upside could be massive. Goldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, es ...

Core Viewpoint - Becton, Dickinson and Company (BD) is positioned for growth through the acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion and the expanding GLP-1 drug delivery market, with a reiterated 'Buy' rating and a fair value of $265 per share [1][18]. GLP-1 Drug Delivery - BD's prefilled syringes and self-administered injection systems are set to capitalize on the rapidly growing GLP-1 drug market, projected to reach $72 billion by 2034 with a CAGR of 11.7% from 2024 to 2034 [2]. - BD has secured a strong market share in the prefilled syringe market, being chosen as a partner for 19 out of 23 new biologic drugs, and has signed 40 GLP-1 biosimilar agreements [3]. - The GLP-1 delivery market is expected to contribute at least $1 billion in revenue by 2030, adding approximately 3% to overall revenue growth [3]. Acquisition of Edwards Lifesciences' Critical Care - The acquisition is seen as value accretive, with the Critical Care business projected to grow at 6%-7% annually and a gross margin exceeding 60% [4]. - BD plans to fund the acquisition with $1 billion in cash and $3.2 billion in new debt, expecting a net debt leverage of 3x post-transaction [4]. - This acquisition is anticipated to enhance BD's technology in monitoring and AI-enabled clinical decision-making, supporting long-term growth in critical care [4]. Recent Results and Outlook - BD reported a 5.2% organic revenue growth and a 22.6% adjusted EPS growth for Q3 FY24, while slightly lowering organic revenue guidance but raising EPS guidance for FY24 [5]. - The Medical Segment is expected to grow by 6%, driven by the GLP-1 drug delivery market, while the Life Sciences Segment is forecasted to grow by 5% as comparable issues from the pandemic fade [5]. - The Interventional Segment is projected to grow by 7%, supported by investments in critical care business units [5]. Valuation - BD is estimated to achieve an 8% total revenue growth in the near future, with a DCF model indicating a fair value of $265 per share [7][15]. - The company anticipates margin expansion through new product launches and operational efficiencies, contributing to overall profitability [7]. Conclusion - The GLP-1 drug delivery market and the acquisition of the Critical Care product group are key drivers for BD's growth, reinforcing a positive outlook with a 'Buy' rating and a fair value of $265 per share [18].

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher do ...

Company Overview - Integrated Ventures Inc. has launched a fully funded subsidiary, MedWellDirect, LLC, which focuses on Direct-To-Consumer telemedicine solutions for weight loss and GLP-1 products [1] - The company has acquired a 51% stake in GetTrim.Com, a telemedicine weight loss services provider owned by Healthy Lifestyle USA [1] Industry Positioning - This strategic move positions Integrated Ventures at the forefront of the rapidly expanding medical weight loss industry, driven by increasing consumer adoption of medications like Semaglutide and Tirzepatide [2] - The telemedicine market for weight loss solutions is experiencing significant growth, indicating a strong shift towards these services [4] Platform and Technology - Healthy Lifestyle USA has developed two consumer-targeted platforms, GetTrim.Com and JoinTrim.Com, offering effective weight loss solutions supported by advanced technology and marketing strategies [3] - The platforms utilize a unified, cloud-based architecture that ensures scalability, reliability, and compliance with HIPAA and GDPR regulations [5] Market Reach and Compliance - The GetTrim platform is compliant to operate in 49 states, including major markets such as California, Florida, Texas, and New York, allowing it to reach a broad audience [6] - This extensive reach aligns with Integrated Ventures' growth strategy to become a leading player in the medical weight loss sector [6] Leadership Perspective - The CEO of Integrated Ventures emphasized that the acquisition of GetTrim.Com is central to the company's B2C/D2C growth strategy and reflects its commitment to high-growth sectors [7]

Core Insights - The rise of GLP-1 weight-loss treatments highlights the significance of protein in preventing muscle loss, leading to increased popularity of high-protein diets like keto and carnivore [1] - The addition of beef to restaurant menus has positively impacted sales, with several restaurant stocks benefiting from this trend [1] Company Summaries Sweetgreen - Sweetgreen Inc. has shifted its focus by adding beef options to its menu, which has attracted a broader customer base beyond health-conscious diners [2] - The introduction of grass-fed Caramelized Garlic Steak in Q1 2024 resulted in 20% of dinner orders including steak, contributing to a 5% year-over-year increase in comparable sales, which rose to 9% in Q2 2024 [3] CAVA Group - CAVA Group Inc. reported a remarkable 14.4% year-over-year growth in comparable sales for Q2 2024, alongside a 35.2% increase in revenue and the opening of 78 new restaurants [4] - The rollout of grilled steak, tested in December 2023, was added to the core menu in June 2024, with expectations for significant impact on Q3 2024 earnings [6] Texas Roadhouse - Texas Roadhouse Inc. operates over 700 steakhouse-style restaurants, with beef as its primary offering, and reported a 9.3% year-over-year growth in comparable sales for Q2 2024, outperforming competitors [7][8] Chili's Grill and Bar - Chili's Grill and Bar, owned by Brinker International Inc., achieved a 14.8% year-over-year growth in comparable sales in Q2 2024, largely due to the viral success of its Big Smasher burger [9][12] - The Big Smasher campaign has positioned Chili's as a direct competitor to fast-food chains, leveraging social media for increased visibility and sales growth [11][12]

Core Thesis - Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biotechnology company focused on developing novel treatments for metabolic and endocrinology disorders, with its leading program VK2735 targeting obesity through dual agonism of GLP-1 and GIP receptors [2][3] VK2735 Development - VK2735 has two formulations: a subcutaneous weekly injection nearing the end of Phase II trials and a daily oral tablet expected to enter Phase II in Q4 2024 [2][3][10] - The subcutaneous formulation has shown promising results, achieving a weight loss of up to 14.7% from baseline in 13 weeks, with a low incidence of severe treatment-emergent adverse events [8][9] - The oral formulation has demonstrated a weight loss of up to 5.3% from baseline in Phase I trials, with good tolerability and safety results [10][12] Competitive Landscape - The obesity drug market is currently dominated by Eli Lilly and Novo Nordisk, but VK2735 could be the first oral GLP-1/GIP dual agonist if approved [3][13] - Other competitors include Amgen, AstraZeneca, and Roche, with several candidates in Phase II or above, indicating a highly competitive environment [13][14] - VK2735's clinical performance is favorable compared to competitors, with the potential for significant market impact if it successfully navigates regulatory approval [15][22] Financial Overview - Viking reported $942 million in cash and equivalents as of June 2024, a 139.8% increase from the previous year, providing a cash runway for approximately four years [16][17] - The company incurred a net loss of $49.606 million in H1 2024, with anticipated costs for the Phase III trial of VK2735 estimated at $300 million [17][18] Valuation and Market Performance - Viking's shares have increased by 245% year-to-date, with a current price around $63, showing signs of recovery after recent market fluctuations [18][19] - Analysts have a consensus rating of "Strong Buy" for VKTX, with a projected upside potential of 77% over the next twelve months [19][20]

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV). Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08280GLP-1.asp According to Research and Markets, The global GLP-1 ...

TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding health and wellness sector. The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets. MedWell USA will be ...

SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients will now have access to once-weekly injectable GLP-1 medication offerings ...